

Highlights of This Issue 1145

REVIEW

- 1147** Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes
Arthur Winer, Sylvia Adams, and Paolo Mignatti

SMALL MOLECULE THERAPEUTICS

- 1156** ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Hetal Patel, Manikandan Periyasamy, Georgina P. Sava, Alexander Bondke, Brian W. Slafer, Sebastian H. B. Kroll, Marion Barbazanges, Richard Starkey, Silvia Ottaviani, Alison Harrod, Eric O. Aboagye, Laki Buluwela, Matthew J. Fuchter, Anthony G. M. Barrett, R. Charles Coombes, and Simak Ali
- 1167** APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
Cheng-Yu Tsai, Si Sun, Hongying Zhang, Andrea Local, Yongxuan Su, Larry A. Gross, William G. Rice, and Stephen B. Howell
- 1177** APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells
Andrea Local, Hongying Zhang, Khalid D. Benbatoul, Peter Folger, Xia Sheng, Cheng-Yu Tsai, Stephen B. Howell, and William G. Rice
- 1187** Anti-*hTERT* siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft
Giovanni E. Lombardo, Valentina Maggisano, Marilena Celano, Donato Cosco, Chiara Mignogna, Federica Baldan, Saverio M. Lepore, Lorenzo Allegri, Sonia Moretti, Cosimo Durante, Giuseppe Damante, Massimo Fresta, Diego Russo, Stefania Bulotta, and Efsio Puxeddu
- 1196** Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting
Buddhadev Layek, Tanmoy Sadhukha, Jayanth Panyam, and Swayam Prabha

- 1207** The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown *In Vitro* and as Orthotopic Xenografts
Cindy R. Timme, Barbara H. Rath, John W. O'Neill, Kevin Camphausen, and Philip J. Tofilon
- 1217** Tetrandrine (TET) Induces Death Receptors Apo Trail R1 (DR4) and Apo Trail R2 (DR5) and Sensitizes Prostate Cancer Cells to TRAIL-Induced Apoptosis
Gauri Shishodia, Sweaty Koul, Qin Dong, and Hari K. Koul
- 1229** Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation
Min-Bin Chen, Yuan-Yuan Liu, Zhao-Yu Xing, Zhi-Qing Zhang, Qin Jiang, Pei-Hua Lu, and Cong Cao
- 1240** Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase
Christopher R. Chitambar, Mona M. Al-Gizawiy, Hisham S. Alhajala, Kimberly R. Pechman, Janine P. Wereley, Robert Wujek, Paul A. Clark, John S. Kuo, William E. Antholine, and Kathleen M. Schmainda

LARGE MOLECULE THERAPEUTICS

- 1251** Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs
Maire F. Osborn, Andrew H. Coles, Diane Golebiowski, Dimas Echeverria, Michael P. Moazami, Jonathan K. Watts, Miguel Sena-Esteves, and Anastasia Khvorova
- 1259** Acquired Resistance to a MET Antibody *In Vivo* Can Be Overcome by the MET Antibody Mixture Sym015
Sofie Ellebæk Pollmann, Valerie S. Calvert, Shruti Rao, Simina M. Boca, Subha Madhavan, Ivan D. Horak, Andreas Kjær, Emanuel F. Petricoin, Michael Kragh, and Thomas Tuxen Poulsen
- 1271** IMG779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
Yelena Kovtun, Paul Noordhuis, Kathleen R. Whiteman, Krystal Watkins, Gregory E. Jones, Lauren Harvey, Katharine C. Lai, Scott Portwood, Sharlene Adams, Callum M. Sloss, Gerrit Jan Schuurhuis, Gert Ossenkoppele, Eunice S. Wang, and Jan Pinkas

Table of Contents


CANCER BIOLOGY AND TRANSLATIONAL STUDIES

- 1280** **The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic *BRAF* Mutant Colorectal Cancer**
Nicholas Forsythe, Alaa Refaat, Arman Javadi, Hajrah Khawaja, Jessica-Anne Weir, Heba Emam, Wendy L. Allen, Frank Burkamp, Vlad Popovici, Puthen V. Jithesh, Claudio Isella, Melissa J. Labonte, Ian G. Mills, Patrick G. Johnston, and Sandra Van Schaeybroeck
- 1291** **Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer**
 Sen Xu, Zongyuan Yang, Ping Jin, Xin Yang, Xiaoting Li, Xiao Wei, Ya Wang, Sixiang Long, Taoran Zhang, Gang Chen, Chaoyang Sun, Ding Ma, and Qinglei Gao
- 1303** **Nuclear Factor- κ B Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling**
Satoshi Inoue, Hiroki Ide, Taichi Mizushima, Guiyang Jiang, George J. Netto, Momokazu Gotoh, and Hiroshi Miyamoto

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 1315** **Analysis of HSP27 and the Autophagy Marker LC3B⁺ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients**
J. Andrew Livingston, Wei-Lien Wang, Jen-Wei Tsai, Alexander J. Lazar, Cheuk Hong Leung, Heather Lin, Shailesh Advani, Najat Daw, Janice Santiago-O'Farrill, Mario Hollomon, Nancy B. Gordon, and Eugenie S. Kleinerman

 **AC icon indicates AuthorChoice**
For more information please visit www.aacrjournals.org

- 1324** **Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial**
Vasiliki Pelekanou, William E. Barlow, Zeina A. Nahleh, Brad Wasserman, Ying-Chun Lo, Marie-Kristin von Wahlde, Daniel Hayes, Gabriel N. Hortobagyi, Julie Gralow, Debu Tripathy, Peggy Porter, Borbala Szekely, Christos Hatzis, David L. Rimm, and Lajos Pusztai
- 1332** ***BRAF* Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors**
 Camilla Stagni, Carolina Zamuner, Lisa Elefanti, Tiziana Zanin, Paola Del Bianco, Antonio Sommariva, Alessio Fabozzi, Jacopo Pigozzo, Simone Mocellin, Maria Cristina Montesco, Vanna Chiarion-Sileni, Arcangela De Nicolo, and Chiara Menin


MODELS AND TECHNOLOGIES

- 1341** **Mechanistic Modeling of Antibody–Drug Conjugate Internalization at the Cellular Level Reveals Inefficient Processing Steps**
Kenneth R. Durbin, Colin Phipps, and Xiaoli Liao

Table of Contents

ABOUT THE COVER

Cover image adapted from Figure 1A, published in Osborn et al., beginning on page 1251. Here, molecular modeling has been used to generate a three-dimensional (3D) representation of a chemically modified, cholesterol-conjugated, self-delivering siRNA (hsiRNA). hsiRNAs are capable of rapid membrane association via cholesterol intercalation into lipid bilayers. These modifications enable siRNA delivery into cells that are notoriously difficult to transfect, including neurons, astrocytes, and as shown in this manuscript, primary human gliomas. Key—Dark purple: cholesterol; light purple: linker; purple: terminal 5'-phosphate; red: phosphorothioate backbone substitutions; black: 2'-O-methyl nucleotide; gray: 2'-fluoro nucleotide.



Molecular Cancer Therapeutics

17 (6)

Mol Cancer Ther 2018;17:1145-1351.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/17/6>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/17/6>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.